Gerard Ber
CIK 1762144 · last filed 2026-06-03
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$2.78M
Companies
3
Total Filings
27
Lifetime Open-Market Net
-$1.58M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| LNTH | Director | 27,118 | $102.64 | $2.78M | -$1.57M | 15 | 2026-06-03 |
| Y-mAbs Therapeutics, Inc. (YMAB) Delisted | Director | 1,608 | $8.61 | $13.8K | -$8.7K | 6 | 2024-06-11 |
| PROGENICS PHARMACEUTICALS INC (PGNX) Delisted | Director | — | — | — | $0 | 2 | 2019-12-17 |
Recent Filings · Page 2 of 3
27 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-05-13 | LNTH | Grant (A) | +2,635 | $0 | EDGAR |
| 2023-06-09 | Y-mAbs Therapeutics, Inc. (YMAB) Delisted | Grant (A) | +2,330 | $0 | EDGAR |
| 2023-05-15 | LNTH | Grant (A) | +2,012 | $0 | EDGAR |
| 2022-07-19 | Y-mAbs Therapeutics, Inc. (YMAB) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-05-12 | LNTH | Grant (A) | — | $0 | EDGAR |
| 2022-05-12 | LNTH | Sell (S) | −1,277 | -$74.3K | EDGAR |
| 2022-05-10 | LNTH | Grant (A) | +2,180 | $0 | EDGAR |
| 2021-06-14 | Y-mAbs Therapeutics, Inc. (YMAB) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-05-12 | LNTH | Grant (A) | +8,513 | $0 | EDGAR |
| 2020-10-05 | LNTH | Grant (A) | +1,065 | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.